Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

BacterioFiles

434: Killer Carries Compact Cas

28 Sep 2020

Description

This episode: Large phage discovered that contains a compact version of the CRISPR/Cas defense/gene editing system! Download Episode (5.9 MB, 8.6 minutes) Show notes: Microbe of the episode: Stenotrophomonas virus IME13 News item Takeaways CRISPR/Cas systems have made a lot of things in gene editing much easier in certain organisms. It's almost as easy as just getting the cells to produce the Cas protein and putting in an RNA sequence to tell it where to go! But in some cases, these requirements are too much to work well.   In this study, a more compact version of CRISPR/Cas was discovered in large bacteriophages. These systems help the viruses compete with other viruses and defend against host defenses sometimes. The Cas protein is half the size of the standard Cas most used in gene editing, and it has fewer other requirements to function in new cells, so it could be better in versatility and potential in applications with strict space constraints. Journal Paper: Pausch P, Al-Shayeb B, Bisom-Rapp E, Tsuchida CA, Li Z, Cress BF, Knott GJ, Jacobsen SE, Banfield JF, Doudna JA. 2020. CRISPR-CasΦ from huge phages is a hypercompact genome editor. Science 369:333–337. Other interesting stories: Example of how cooperation becomes more beneficial than independence Programming bacteria to detect and kill specific other microbes in a mixed community (paper)   Email questions or comments to bacteriofiles at gmail dot com. Thanks for listening! Subscribe: Apple Podcasts, Google Podcasts, Android, or RSS. Support the show at Patreon, or check out the show at Twitter or Facebook.

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.